New drug joins fight against deadly brain tumors
NCT ID NCT06806228
Summary
This early-stage study is testing whether adding an experimental drug called S-Gboxin to standard brain cancer treatment helps control aggressive tumors like glioblastoma. It will involve about 10 patients with these difficult-to-treat cancers. Researchers will monitor how patients tolerate the combination and look for early signs that the treatment is working by tracking tumor size and patient survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kazakh Institute of Oncology and Radiology
Almaty, 490 078, Kazakhstan
-
National Cancer Institute
Kyiv, 33/43, Ukraine
-
Tbilisi Cancer Centre
Tbilisi, 0198, Georgia
Conditions
Explore the condition pages connected to this study.